20
Participants
Start Date
April 30, 2015
Primary Completion Date
July 31, 2016
Study Completion Date
July 31, 2016
AlloHCT for Young/MSD
Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
AlloHCT for Young/MUD&FMD
Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
AlloHCT for Old/MSD
Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
AlloHCT for Old/MUD&FMD
Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
Inje University Busan Paik Hospital, Busan
Inje University Haeundae Paik Hospital, Busan
Asan Medical Center, University of Ulsan College of Medicine, Seoul
Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan
Lead Sponsor
Asan Medical Center
OTHER